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Angiotensin converting enzyme gene polymorphism and ACE inhibition
in diabetic nephropathy. The antiproteinuric effect of angiotensin con-
verting enzyme (ACE) inhibition in insulin-dependent diabetes mellitus
(IDDM) patients with diabetic nephropathy varies considerably. There-
fore, we tested the potential role of an insertion (I)/deletion (D) polymor-
phism of the ACE gene on this early antiproteinuric responsiveness in an
observational follow-up study. Sixty (II, N 5 13; ID, N 5 26 and DD, N 5
21) young hypertensive IDDM patients suffering from diabetic nephrop-
athy were investigated during three months before and for the initial six
month period during ACE inhibition [captopril 44 (SD 22) mg/24 hr, no
differences in drug dose between groups]. Blood pressure (MABP) and
albuminuria (ELISA) were measured three (1 to 6) times before and three
(1 to 13) times during ACE inhibition. At baseline the groups (II/ID/DD)
had comparable (1) mean arterial blood pressure (MABP mm Hg) of
113 6 10/108 6 9/114 6 8, (2) albuminuria (geometric mean with 95% CI)
1394 (747 to 2608)/1176 (844 to 1797) and 1261 (827 to 2017) mg/24 hr,
and (3) serum creatinine (geometric mean with 95% CI), 80 (68 to 93)/85
(76 to 97)/103 (85 to 119) mmol/liter, respectively. Angiotensin converting
enzyme inhibition induced a significant reduction in MABP, albuminuria
and kidney function in all three groups (II/ID/DD; P , 0.05): (1) MABP
(mean 6 SD) 12 6 7/5 67/8 6 9 mm Hg (ANOVA, P 5 0.02); (2)
albuminuria [mean (95%CI)] 61 (34 to 77)/22 (3 to 37)/31 (13 to 46) %,
(ANOVA, P , 0.01); and (3) increasing serum creatinine [mean (95%CI)]
8 (4 to 12)/9 (3 to 16)/8 (0 to 16) % (ANOVA, NS), respectively. Adjusting
for differences in reduction in MABP did not change the association
between decrease in albuminuria and ACE/ID genotypes (P , 0.01). A
multiple linear regression analysis revealed that the ACE/ID polymor-
phism, albuminuria and MABP at baseline independently influenced the
decline in albuminuria after initiation of ACE inhibition (R2 5 0.21, P ,
0.01). A significant association between changes in MABP and albumin-
uria was demonstrated (R2 5 0.16, P , 0.01). Our data show that
hypertensive albuminuric IDDM patients with the II genotype are partic-
ularly susceptible to commonly advocated renoprotective treatment.
Albuminuria is a risk factor for progression of diabetic ne-
phropathy [1, 2]. Antihypertensive treatment, especially angioten-
sin converting enzyme (ACE) inhibition, has been shown to
reduce albuminuria and to ameliorate progression of diabetic
nephropathy in IDDM patients [3]. Studies of diabetic and
non-diabetic kidney disease suggest that reduction in albuminuria
during the initial six-month treatment period after the start of
ACE inhibition predicts an attenuated rate of decline in glomer-
ular filtration rate [4–6]. As a consequence, early reduction in
albuminuria during ACE inhibition can be regarded as a surro-
gate end point for the prognosis of diabetic nephropathy. The
antiproteinuric response to ACE inhibition varies considerably
between patients. Individual differences in the renin-angiotensin
and kallekrein-kinin systems may influence this variation. Re-
cently, an insertion(I)/deletion(D) polymorphism of the ACE
gene (ACE/ID) has been shown to influence the antiproteinuric
efficacy of ACE inhibition in non-diabetic kidney disease [7–10]
and the deterioration in kidney function in both diabetic and
non-diabetic kidney disease [7, 8, 11–14].
We tested the potential role of the ACE/ID polymorphism on
the antiproteinuric responsiveness to ACE inhibition during the
initial six-month treatment period in an observational follow-up
study of IDDM patients with diabetic nephropathy.
METHODS
Research design
We examined the records of all patients with albuminuria attend-
ing the outpatient clinic at Steno Diabetes Center in 1993 who had
IDDM and diabetic nephropathy, and who had their glomerular
filtration rates (GFRs) measured during the same year (before
and/or after antihypertensive treatment). A total of 242 Caucasian
patients more than 18 years of age were identified. Angiotensin
converting enzyme genotyping was performed in 198 of them as
described in detail previously [15]. Lymphocytes were isolated
from blood, and DNA was prepared by standard techniques.
Polymerase chain reaction (PCR) was used to detect the two
alleles of the ID polymorphism. DNA was amplified using primers
and PCR-cycling conditions as described previously [16]. In our
laboratory, this method yielded no discrepancy with the results
obtained using a new procedure with an additional allele-specific
primer in the insertion sequence, when tested on 50 samples (11
DD, 30 ID, 9 II) from the ECTIM study [17]. Subjects were
classified according to the presence (I) or absence (D) of a 287
base pair insertion in intron 16 of the ACE gene into II, ID or DD
genotypes. We identified all patients who had never received
antihypertensive treatment (N 5 55) or had their antihypertensive
treatment withdrawn (N 5 16) for at least one month before the
initiation of ACE inhibition. Eleven of the previously untreated
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patients could not be evaluated in the present study since data on
albuminuria and serum creatinine during the initial six-month
treatment period were lacking (see below). The remaining sixty
patients (II, N 5 13; ID, N 5 26; DD, N 5 21) fulfilled the
inclusion criteria and all gave fully informed consent. The dose of
captopril, given b.i.d., was titrated to achieve a reduction in blood
pressure to , 140/90 mm Hg or at least 10/5 mm Hg below
baseline. In an attempt to achieve this goal or because of edema
20 patients had a diuretic added. Apart from this addition, no
other antihypertensive drugs were used. The long-term effect of
ACE inhibition in relation to the ACE/ID polymorphism has
previously been described in 24 of the current previously-un-
treated patients and in the excluded eleven patients mentioned
above [11]. The experimental design was approved by the local
ethical committee. The patients had diabetic diet (45 to 55%
carbohydrates, 30 to 35% fat, and 15 to 20% protein) without
restriction in sodium or protein intake. Measurements of albu-
minuria and blood pressure were carried out one to six (median 3)
times within three months before the start of treatment with an
ACE inhibitor in the previously untreated patients (N 5 44, NS
between groups), and three times one month after withdrawal of
other antihypertensive treatment in the previously treated pa-
tients (N 5 16). During the first six months of ACE inhibitor
treatment albuminuria and blood pressure were measured 1 to 13
(median 3) times (NS between groups). The mean duration after
ACE inhibition of albuminuria assessment was the same in the
three groups [II, 3 months (range 1 to 6 months); ID, 3 months (1
to 6); and DD 3 months (2 to 6)]. Urinary albumin concentration
was determined by an enzyme immunoassay from all 24-hour
urine collections made at home and during the four-hour clear-
ance period when GFR was measured [18]. More than 90% of all
albuminuria measurements in each of the three groups were
based on 24-hour urine collections (NS between groups). Arterial
blood pressure was measured with a standard clinical mercury
sphygmomanometer (cuff 25 cm 3 12 cm) on the right arm while
the patient was sitting after 10 minutes of rest. Diastolic blood
pressure was recorded at the disappearance of the Korotkoff
sounds (phase V). Mean arterial blood pressure (MABP) was
calculated as diastolic blood pressure plus one third of the pulse
amplitude. Serum creatinine concentration was assessed by a
kinetic Jaffe method before and six months after the start of ACE
inhibition. Forty-seven patients had their GFR measured before
and 48 after the initiation of ACE inhibition by applying a single
injection, 51Cr-EDTA (3.7 MBq) four-hour plasma clearance
technique [19]. Only 38 patients had their GFRs measured both
before and during ACE inhibition (data not shown). Hemoglobin
A1C (HbA1C) concentration from venous blood samples was
determined by high performance liquid chromatography
(DIAMAT Analyzer; Bio-Rad, Richmond, CA, USA). Serum
cholesterol concentrations were measured by a conventional
laboratory technique. Diabetic retinopathy was assessed by fundus
photography after pupillary dilation.
Statistical analysis
Values are given as means 6 SD, except for urinary albumin
concentration and serum creatinine, which are expressed as
geometric means with a 95% confidence interval (CI) owing to the
skewed distribution. The calculations of baseline values of albu-
minuria and arterial blood pressure for each patient include all
values measured within three months prior to initiation of ACE
inhibitor treatment in previously untreated patients and values
measured one month after the withdrawal of other antihyperten-
sive drugs in previously treated patients. Calculations of albumin-
uria and blood pressure during ACE inhibition for each patient
include all values measured from one to six months after initiation
of ACE inhibitor treatment. For normally distributed variables,
including logarithmically transformed values of urinary albumin
concentration and serum creatinine, the three groups were com-
pared by a one-way analysis of variance (ANOVA). Significant
ANOVAs were followed by a pair-wise comparison uring Schef-
fe’s test. For non-normally distributed continuous variables the
three groups were compared by the Kruskal-Wallis test. A paired
Student’s t-test was used to compare albuminuria, blood pressure
and serum creatinine before and after the start of ACE inhibition
within the groups. A linear regression analyses of albuminuria
change (logarithmical) versus blood pressure change for each of
the groups and all 60 patients were performed. A multivariate
stepwise linear regression analysis of putative risk factors influ-
encing the change in albuminuria after start of ACE inhibition
was performed with backward selection. Angiotensin converting
enzyme I/D genotype was entered as an ordered categorical
variable (II 5 1, ID 5 2, DD 5 3) due to the relationship between
genotype and serum ACE activity. The R2 value is adjusted for the
number of variables introduced into the model. A P value (two
sided) of , 0.05 was considered to be significant. All calculations
were performed using SPSS (SPSS, Chicago, IL, USA).
RESULTS
At baseline the three groups with different genotypes were
similar with regard to sex, age, duration of diabetes, body mass
index, insulin dose, frequency of retinopathy, glycemic control,
MABP, albuminuria, serum creatinine and serum cholesterol
(Table 1). The dose of captopril (mg/24 hr) [42 (22)/43 (23)/47
(21)], and the number of patients receiving a diuretic after starting
ACE inhibition (N 5 5/7/8) were also similar in the patients with
II, ID and DD genotypes, respectively (NS).
Initiation of treatment with ACE inhibition induced a signifi-
cant drop in albuminuria in all three groups (P , 0.05), but the
reduction was significantly greater in patients with II genotype,
61% (34 to 77)% [mean (95% CI)], compared to patients with
either ID, 22% (3 to 37%), or DD genotype, 31% (13 to 46%; P ,
0.01; Table 2). The MABP declined during ACE inhibition within
each group (P , 0.01), however, a more pronounced reduction
was observed in the patients with II genotype compared to
patients with ID and DD genotype (P 5 0.02; Table 2). An almost
identical (P 5 0.95 between groups) increase in the serum
creatinine was seen in all groups after the initiation of ACE
inhibition (Table 2).
Plotting change in Log10 (albuminuria) versus change in mean
arterial blood pressure for each of the groups (Fig. 1) revealed the
following regression slopes (95% CI): II, 0.044 (0.024 to 0.064; R2
5 0.65, P 5 0.0005); ID, 20.003 (20.017 to 0.012; R2 5 0.01, P 5
0.67); and DD, 0.008 (20.003 to 0.019; R2 5 0.06, P 5 0.14). A
simple factorial ANOVA of the change in albuminuria including
all 60 patients adjusted for change in MABP revealed an inde-
pendent effect of the ACE genotype (P 5 0.004). The MABP
adjustment was carried out within each of the three groups based
on the above-mentioned regression slopes.
A multiple linear regression analysis revealed that the ACE/ID
Jacobsen et al: ACE gene and ACE inhibition 1003
genotype, baseline albuminuria and baseline MABP indepen-
dently influenced the decline in albuminuria after the start of
ACE inhibition (R2 5 0.21, P , 0.01), while baseline serum
creatinine, HbA1C and captopril dose did not contribute to the
decline. A linear regression analysis revealed a significant corre-
lation between changes in MABP and albuminuria (R2 5 0.16,
P , 0.01).
DISCUSSION
During the initial six months after the beginning of antihyper-
tensive treatment, our observational follow-up study revealed that
ACE inhibition has an antiproteinuric effect in hypertensive
IDDM patients with diabetic nephropathy, and that this beneficial
effect is most pronounced in patients with the insertion allele of
the ACE/ID polymorphism. The latter group also had a slightly
greater reduction in MABP during this initial period of ACE
inhibition, but adjusting for this difference in blood pressure
reduction within each of the three groups did not change the
association between decline in albuminuria and ACE/ID geno-
types. Furthermore, it should be stressed that other factors
influencing albuminuria such as the dose of ACE inhibitor,
glycemic control, and kidney function were comparable between
groups. Thus, our study indicates that the ACE/ID polymorphism,
albuminuria, and MABP at baseline independently influence the
decline in albuminuria after initiation of ACE inhibition. Since
the present data are not based on a randomized, double-blind
treatment trial of the same dose of ACE inhibition, bias must be
taken into account. During the last 10 years ACE inhibition has
been considered the drug of choice in treating IDDM patients
with nephropathy at the Steno Diabetes Center. Treatment with
ACE inhibitors was independent of genotype and none of the
patients stopped ACE inhibition during the study, thus accounting
for all enrolled patients. Furthermore, the distribution of geno-
types in patients enrolled in the present study did not differ from
the genotype distribution observed among hypertensive patients
in the original cohort [20]. Finally, baseline clinical and laboratory
data were the same in the different genotype groups.
Recently, the Euclid Study Group examined the effect of the
ACE/ID polymorphism on the antiproteinuric responsiveness to
ACE inhibition in a randomized, double-blind placebo controlled
trial of lisinopril (10 mg/day) in 530 normotensive IDDM patients
with normo- or microalbuminuria [21]. At two years, urinary
albumin excretion rate was 57% lower on lisinopril in the II group,
19% lower in the ID group, and 19% higher in the DD group as
compared to placebo. In contrast, previous short-term studies
dealing with a variety of non-diabetic kidney diseases have yielded
conflicting results regarding the antiproteinuric effect during
ACE inhibition in relation to the ACE/ID polymorphism [8–10,
22]. However, long-term studies dealing with larger numbers of
patients with different non-diabetic nephropathies have revealed
that neither ACE inhibition nor a b-blocker lowered the degree of
proteinuria in the DD group, while the ID and II groups were
both sensitive to the antiproteinuric effect [7].
Originally, Rigat et al [23] demonstrated that plasma ACE
Table 2. Effect of ACE inhibition in 60 IDDM patients with diabetic
nephropathy according to ACE/ID genotypes
Genotype
P valueII ID DD
Number 13 26 21
Decline in MABP mm Hg 12 (7) 5 (7) 8 (9) 0.02b
Decline in albuminuria
%a
61 (34–77) 22 (3–37) 31 (13–46) , 0.01c
Increase in serum
creatinine %a
8 (4–12) 9 (3–16) 8 (0–16) NS
Values are means (SD).
a mean (95% C.I.)
b P , 0.05 for II versus ID, NS between other pairwise comparisons
c P , 0.05 for II versus ID and II versus DD
Table 1. Clinical and laboratory data at baseline in 60 IDDM patients with diabetic nephropathy according to insertion (I)/deletion (D)
polymorphism in the ACE gene (ACE/ID genotypes)
II genotype ID genotype DD genotype P value
No. of men/women 7/6 17/9 17/4 NS
Age years 35 (5) 39 (9) 40 (8) NS
Duration of diabetes years 20 (7) 19 (5) 22 (9) NS
No. of patients with retinopathy
Simplex 3 10 10 NS
Proliferative 10 16 11 NS
Insulin dose IU/kg/24 hr 0.7 (0.1) 0.7 (0.2) 0.6 (0.2) NS
Body mass index kg/m2 24.2 (4.0) 23.5 (2.1) 24.4 (2.9) NS
HbA1C % 9.3 (0.9) 9.3 (1.4) 9.1 (1.0) NS
MABP mm Hg 113 (10) 108 (9) 114 (8) 0.07
Albuminuria mg/24 hra 1394 (747–2608) 1176 (844–1797) 1261 (827–2017) NS
Serum creatinine mmol/litera 80 (68–93) 85 (76–97) 103 (85–119) 0.08
GFR ml/min/1.73m2b 94 (22) 96 (27) 85 (26) NS
Serum cholesterol mmol/liter 5.4 (0.9) 5.5 (1.2) 5.6 (1.0) NS
Antihypertensive treatment
during study
Captopril dose mg/24 hr 42 (22) 43 (23) 47 (21) NS
Frusemide mg/24 hrc 80 (40–1000) 100 (40–200) 50 (40–160) NS
No. of patients taking
frusemide
5 7 8 NS
Values are means (SD).
a geometric mean with 95% CI
b Values based on 47 patients (II, ID, DD: N 5 10, N 5 18, N 5 19, respectively)
c median (range)
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levels in DD subjects were twice that of II subjects, with ID
subjects having intermediate levels. We found a similar associa-
tion in IDDM patients with diabetic nephropathy [15]. The
patients studied at present constitute a subset of this former study.
Angiotensin converting enzyme is of importance in regulating
systemic and glomerular circulation by converting angiotensin I
into angiotensin II and inactivating bradykinin. Increased synthe-
sis of angiotensin II may play a role in the progression of
albuminuria and glomerular filtration rate in diabetic nephropa-
thy by hemodynamic mechanisms, that is, systemic and glomerular
hypertension and by growth promoting effects on glomerular cells,
particularly mesangial cells [24]. Enhanced systemic pressure
response to intravenous infusion of angiotensin I, in normotensive
non-diabetic subjects homozygous for the DD allele of the ACE
gene as compared to the II genotype, has been reported [25]. The
same group demonstrated in a double blind, cross-over design
that the attenuation of the intravenous angiotensin I pressor
response by 0.01 mg of enalapril was significantly greater and
lasted longer in non-diabetic normotensive subjects homozygous
for the II ACE genotype, suggesting that the ACE I/D polymor-
phism may differentiate responses to ACE inhibition [26]. Addi-
tional explanations for the deleterious effect of the deletion
polymorphism on albuminuria may be elevated intrarenal angio-
tensin II formation and/or insufficient angiotensin converting
enzyme inhibition.
The antiproteinuric effect during ACE inhibition is in part
dependent on the reduction of systemic blood pressure and
particularly on the degree of transmission of the systemic pressure
to the glomerular capillaries. The systemic blood pressure reduc-
tion was greater in the II group as compared to the two other
groups, but even after an adjustment for this difference the data
still suggest that the II genotype is particularly susceptible to ACE
inhibition. In addition to the hemodynamic effect of ACE inhibi-
tion on albuminuria, non-hemodynamic effects such as reduction
in pore size in the glomerular capillaries have been documented
[27]. Furthermore, the maximum antiproteinuric effect of ACE
inhibition usually occurs after two to four weeks, which suggests
contribution from non-hemodynamic mechanisms [28]. Protein
and sodium restriction was not applied in our study and approx-
imately the same number of patients (27 to 40%) within the three
genotype groups received diuretics. A previous study has docu-
mented that severe sodium restriction potentiates the antiprotein-
uric effect of ACE inhibition in non-diabetic kidney diseases [29].
None of our patients received non-steroidal anti-inflammatory
drugs or other compounds known to influence albuminuria during
the study period. These findings and the multiple linear regression
analysis suggest that hypertensive macroalbuminuric IDDM pa-
tients with the II/ACE genotype are particularly susceptible to the
commonly advocated renoprotective therapy.
Previous studies in diabetic [4, 6, 30] and non-diabetic kidney
disease [5] have indicated that the initial degree of reduction in
albuminuria after the start of antihypertensive treatment with or
without ACE inhibition is highly predictive for future progression
in GFR, that is, patients with the largest initial reduction in
albuminuria have the smallest subsequent rate of decline in GFR.
All previous studies in non-diabetic and diabetic nephropathies
have demonstrated that the deletion polymorphism of the ACE
gene, particularly the homozygote DD, is a risk factor for an
accelerated loss of kidney function [7, 11, 12, 22]. Furthermore,
the deletion polymorphism in the ACE gene reduces the long-
term beneficial effect of ACE inhibition on progression of dia-
betic and non-diabetic kidney disease [7, 11].
Our data show that hypertensive albuminuric IDDM patients
with the II genotype are particularly susceptible to the commonly
advocated renoprotective treatment.
Reprint requests to Dr. Hans-Henrik Parving, Steno Diabetes Center, Niels
Steensens Vej 2, DK-2820 Gentofte, Denmark.
APPENDIX
Abbreviations used in this article are: ACE, angiotensin converting
enzyme; D, deletion genotype; GFR, glomerular filtration rate; HbA1C,
hemoglobin A1C; I, insertion genotype; IDDM, insulin-dependent diabe-
tes mellitus; MABP, mean arterial blood pressure; PCR, polymerase chain
reaction.
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